Although men and women with advanced kidney disease experienced physical and mental declines in health-related quality of life (QOL), men’s declines occurred at a significantly faster rate, researchers concluded.
Despite women with chronic kidney disease (CKD) presenting with a lower health-related quality of life at the onset of a recent study, men were found to have their quality of life decline more rapidly over time, investigators concluded.
Although the study, published in the Clinical Journal of the American Society of Nephrology, showed declines in in physical and mental aspects of quality of life in both men and women diagnosed with advanced kidney disease, it revealed the stark differences in the speed at which the declines may occur.
“It is increasingly being accepted that the patient's health-related quality of life is as equally important as other clinical outcomes when assessing a patient’s health status….Very few studies have investigated the interdependence of health-related quality of life and sex over time in older patients with advanced CKD. CKD is highly prevalent in this age group, and given the rising life expectancy, efforts to improve health-related quality of life in the elderly should remain in focus,” said Nicholas Chesnaye, PhD, the lead study author from the Amsterdam Public Health Research Institute, in a statement.
The researchers analyzed responses to questionnaires collected as part of the European Quality Study on treatment in patients with advanced CKD, which included patients aged 65 years and older with advanced CKD who were not receiving hemodialysis therapy. The patients had to be receiving routine medical care in Germany, Italy, the Netherlands, Poland, Sweden, or the United Kingdom.
Responses from 1421 patients were utilized in the analysis. At baseline, women were reported to have considerably lower physical and mental health scores on average compared with their male counterparts. However, during the follow-up period, the investigators found that the physical (2.5 per year; 95% CI, 1.8-3.1) and mental (2.7 per year; 95% CI, 2.0-3.4) scores for men declined about twice as fast compared with women (physical: 1.1 per year; 95% CI, 0.1 to 2.0; mental: 1.6 per year; 95% CI, 0.7 to 2.6).
After adjusting for confounding factors, including kidney function decline, the differences were lessened somewhat, suggesting that the faster declines in men could be explained by gender differences. The association between men and women remained when adjusting for potential informative censoring due to mortality (23% vs 22%, respectively) or dialysis initiation (38% vs 31%, respectively).
Higher phosphate levels and lower hemoglobin levels were found to have an association with lower physical and mental scores in men. Additionally, pre-existing diabetes was associated with lower scores in men. These associations were also detected in women but to a lesser extent.
“An understanding of sex-specific health-related quality of life over the course of pre-dialysis CKD, as well as the potential mechanisms underlying any differences, may provide insights into a patient’s health and needs, and aid sex-specific clinical monitoring, decisions related to kidney replacement therapy, and patient-centered care,” said Chesnaye.
Reference
Chesnaye NC, Meuleman Y, de Rooji ENM, et al. Health-related quality-of-life trajectories over time in older men and women with advanced chronic kidney disease. Clin J Am Soc Nephrol. January 24, 2022;17(1): doi: 10.2215/CJN.08730621
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
2 Commerce Drive
Cranbury, NJ 08512